INVESTIGATION OF CROSS IMMUNITY FOLLOWING VACCINATION WITH ALLOGENIC CANCER CELL

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。我们目前正在进行一项使用基因修饰癌细胞的肺癌临床疫苗试验。这项正在进行的疫苗研究的设计是为了研究是否会产生特异性针对用作实际疫苗的同种异体细胞系的免疫力。将进行适当的试验，包括细胞毒性T淋巴细胞试验以及细胞因子试验和肿瘤缓解的临床评价。参与受试者已提供适当的知情同意书。为了从存档血液中进行其他重要的免疫学试验，我们提出并由研究者发起。我们建议检查是否对其他肺细胞系的反应已经发展。该应答将特异性针对受试者在接种过程中未接种的细胞系。这些研究将对从未接种受试者（接种前）和4次接种后的受试者的淋巴细胞和血清进行。将这些组织和血清存档并冷冻保存，并在体外进行拟定研究。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. We are currently conducting a lung cancer clinical vaccine trial which is using gene modified cancer cells. The design of this ongoing vaccine study is geared to investigate whether immunity specifically directed against the allogenic cell lines used as the actual vaccine will develop. Appropriate assays will be performed which includes cytotoxic T-lymphocyte assays, as well as cytokine assays and clinical evaluation for tumor responses. Participating subjects already have provided appropriate consents. In order to perform additional important immunological assays from archived blood, we propose and investigator initiated component. We propose to examine whether a response against other lung cell lines has developed. This response would be specifically against cell lines the subjects had not been vaccinated during the vaccination process. These studies will be performed on lymphocytes and serum obtained from naive subjects (prior to vaccination) and subjects following each of the four vaccinations. These tissues and serum are archived and cryopreserved and propsed studies will be conducted in vitro.